Diffusion Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update
08 août 2019 17h15 HE
|
Diffusion Pharmaceuticals Inc.
Company Completes $6.28 Million Registered Direct OfferingFavorable Data Reported in Glioblastoma Multiforme Phase 3 Run-in StudyPhase 2 On-Ambulance TSC Clinical Trial for the Treatment of Stroke...
Diffusion Pharmaceuticals Reports Favorable Safety Data for Dose-Escalation Run-in of Phase 3 INTACT Study in Glioblastoma Multiforme Patients
23 juil. 2019 08h30 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., July 23, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical...
Diffusion Pharmaceuticals Inc. Announces Closing of $6.45 Million Offering Priced At-the-Market
28 mai 2019 16h05 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., May 28, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”) today announced the closing of its previously...
Diffusion Pharmaceuticals Inc. Announces $6.45 Million Registered Direct Offering & Private Placement
24 mai 2019 09h00 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., May 24, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”) today announced that it has entered into a...
Diffusion Pharmaceuticals Receives Notice of Intention to Grant a Patent Related to Use of TSC in Combination with tPA in Ischemic Stroke from European Patent Office
23 mai 2019 07h30 HE
|
Diffusion Pharmaceuticals Inc.
Two Additional European Patents Issued CHARLOTTESVILLE, Va., May 23, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge...
Diffusion Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update
09 mai 2019 16h05 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., May 09, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical...
Diffusion Pharmaceuticals Reports 2018 Financial Results and Provides Business Update
20 mars 2019 09h00 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., March 20, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical...
Poster Presented at International Stroke Conference Describing Diffusion’s On-Ambulance Phase 2 Trial with TSC for Treating Acute Stroke
11 févr. 2019 16h00 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical...
Diffusion Pharmaceuticals Chief Executive Officer David Kalergis to Present at 37th Annual J.P. Morgan Healthcare Conference
04 janv. 2019 09h00 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical...
Diffusion Pharmaceuticals Executes Successful NASDAQ Compliance Plan: Company Will Remain Listed on NASDAQ Stock Market
03 janv. 2019 09h00 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical...